Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 2/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6081734 | 0.82 | ATM (0.44) | ATMNPC1RAB9ABCHEACHE | |
| SCHEMBL8626591 | 0.78 | ATM (0.40) | ATMNPC1RAB9A | |
| SCHEMBL400031 | 0.78 | ATM (0.40) | ATMNPC1RAB9A | |
| SCHEMBL12478396 | 0.77 | ATM (0.39) | ATMNPC1RAB9AKCNH2 | |
| SCHEMBL4620642 | 0.76 | ATM (0.48) | ATMNPC1RAB9APDPK1BCL2 | |
| SCHEMBL4559941 | 0.72 | ATM (0.48) | ATMNPC1RAB9APDPK1 | |
| SCHEMBL3535166 | 0.72 | ATM (0.48) | ATMNPC1RAB9APDPK1 | |
| SCHEMBL5259264 | 0.72 | ATM (0.48) | ATMNPC1RAB9APDPK1 | |
| SCHEMBL8424490 | 0.72 | ATM (0.48) | ATMNPC1RAB9APDPK1 | |
| SCHEMBL8423013 | 0.71 | ATM (0.44) | ATMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| CN-101106998-A | Mitotic kinesin inhibitors | MERCK & CO INC (US) | 2008-01-16 | — | — | CN | disclosed |
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1855685-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006078598-A3 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006078598-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124641-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | ATM 675/4885NPC1 1055/4885RAB9A 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.